Aquestive is betting on a needle-free emergency allergy treatment and other easy-to-take medicines, but getting insurers and doctors on board could take longer than many expect. Competition is heating up too, so the upside depends on both winning coverage and proving patients switch over in the real world.Read more
Aquestive is betting that its needle-free allergy treatment and oral film platform can ride the shift toward at-home care and win patients even when insurers push back. The catch is that the whole story leans heavily on one key product launch, while losses and growing competition could make it harder to scale.Read more
Key Takeaways The FDA review and potential success of Anaphylm could drive strong revenue growth and shift market preference toward needle-free drug delivery. Strategic investments in awareness, payer access, and product pipeline position the company for rapid adoption, diversified revenue, and improved margins.Read more
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company’s proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
